Incidence of Adverse Drug Events in Secondary Hospital at Cabo Verde Identified Using Trigger Tools
|Carla Djamila Reis*, Calida Etzana Veiga and Jailson Jesus Martins|
|Agência de Supervisão e Supervisão de Produtos Farmacêuticos e Alimentares (ARFA), Praia, Cape Verde|
|Corresponding Author :||Carla Djamila Reis
Master in Pharmaceutical Regulation
Agência de Regulação e Supervisão
de Produtos Farmacêuticos e Alimentares (ARFA), Praia, Cape Verde
Tel: 238 262 64 10
E-mail: [email protected]
|Received October 26, 2015; Accepted November 13, 2015; Published November 18, 2015|
|Citation: Reis CD, Veiga CE, Martins JJ (2015) Incidence of Adverse Drug Events in Secondary Hospital at Cabo Verde Identified Using Trigger Tools. J Pharmacovigil 3:183. doi:10.4172/2329-6887.1000183|
|Copyright: © 2015 Reis CD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at Pubmed, Scholar Google|
Background: Adverse drug events (ADE) are a major health and economic problem. There is no information regarding incidence of ADE in Cabo Verde and trigger tools are an efficient active data collection method.
Objective: To develop the first PV study in Cabo Verde and characterize ADE in a hospital.
Method: This is a retrospective study of chart review using the Global Trigger Tool (GTT) developed by the Institute for Healthcare Improvement (IHI). The simple random sample of medical records for patients discharged from October 2012 to March 2013 and from October 2013 to March 2014. Hospitalization for less than 48 h, time spent in intensive care unit and medical records with no drug administration records were excluded.
Results: A total of 383 medical records data were collected. The average age of patients was 37 and 40 years, 62.6% and 59.8% of the total were females. A total 287 triggers were identified, 184 and 103 triggers for first and second period, respectively. For the first period, a total of 105 ADE were identified in 54 patients with the incidence of 28.4% patient presenting ADE and a rate of 54% ADEs per 100 patients, in the second period, a total of 77 ADE were identified in 38 patients with the incidence of 19.6% and a rate of 38% ADE per 100 patients. Drugs more often associated with an ADE were ceftriaxone, furosemide, metronidazole and ranitidine.
Conclusion: The trigger tool had a good performance detecting ADE. About ¼ of the hospitalized patients in hospital showed adverse events. Further studies are needed using prospective method and extended period.